Pomalyst
Named-patient access overview. Pomalyst is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Pomalyst (pomalidomide) is an oral immunomodulatory imide drug (IMiD) developed by Bristol Myers Squibb (Celgene). The US Food and Drug Administration first approved Pomalyst in February 2013 for adult patients with relapsed or refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and who have demonstrated disease progression on or within 60 days of completion of the last therapy. The drug is given as a once-daily oral capsule (1, 2, 3, or 4 mg) on days 1 through 21 of a 28-day cycle, typically combined with dexamethasone. Pomalyst is dispensed under the Pomalyst REMS programme due to embryo-fetal toxicity risk.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Pomalyst
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Pomalyst is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Pomalyst in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Pomalyst
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.